quinazolines has been researched along with exenatide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-kholy, W; MacDonald, PE; Targonsky, ED; Tsushima, RG; Wang, X; Wheeler, MB; Xia, F | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Jermendy, G | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP | 1 |
| Tibaldi, JM | 1 |
3 review(s) available for quinazolines and exenatide
| Article | Year |
|---|---|
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
3 other study(ies) available for quinazolines and exenatide
| Article | Year |
|---|---|
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
Topics: Androstadienes; Animals; Blotting, Western; Catalysis; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Electrophysiology; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Kinetics; Male; Mice; Peptide Fragments; Peptides; Phosphatidylinositol 3-Kinases; Phosphorylation; Potassium; Precipitin Tests; Protein Precursors; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Time Factors; Transcriptional Activation; Tyrphostins; Up-Regulation; Venoms; Wortmannin | 2003 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Hypoglycemic Agents; Inositol; Linagliptin; Male; Peptides; Purines; Quinazolines; Rats; Rats, Zucker; Treatment Outcome; Venoms | 2014 |